<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525237</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-G316</org_study_id>
    <nct_id>NCT02525237</nct_id>
  </id_info>
  <brief_title>Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Qingdao Municipal Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with&#xD;
      S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction&#xD;
      adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Event driven, an expected average of 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety will be assessed by incidence of adverse events</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Event driven, an expected average of 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>An expected average of 24 months</time_frame>
    <description>Quality of life of patient will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQ-C30].</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients, aged ≥18 years;&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the stomach with inoperable locally&#xD;
             advanced or recurrent and/or metastatic disease;&#xD;
&#xD;
          3. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST v1.1);&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3;&#xD;
&#xD;
          5. No previous chemotherapy for advanced/metastatic disease 1) Prior adjuvant/neoadjuvant&#xD;
             therapy is allowed if at least 6 months has elapsed between completion of&#xD;
             adjuvant/neoadjuvant therapy and enrolment into the study); 2) No previous targeted&#xD;
             therapy; 3) For patients who can't tolerate first-line chemotherapy or refuse to&#xD;
             accept chemotherapy, if they request to participate in this study, may receive&#xD;
             apatinib monotherapy after consultation with the principal investigator in&#xD;
             consideration of ethics.&#xD;
&#xD;
          6. Hematological, Biochemical and Organ Functions: HB ≥ 80 g/L, ANC ≥ 1.5×109/L, PLT ≥&#xD;
             80×109/L, BIL &lt; 1.5×ULN, ALT or AST &lt; 2.5×ULN (or &lt; 5×ULN in patients with liver&#xD;
             metastases), Serum Cr ≤ 1×ULN, Cr clearance ≥ 50 mL/min;&#xD;
&#xD;
          7. Life expectancy of more than 3 months;&#xD;
&#xD;
          8. Duration from operation is more than 4 weeks;&#xD;
&#xD;
          9. For women of child-bearing age, the pregnancy test results (serum or urine) within 7&#xD;
             days before enrolment must be negative. They will take appropriate methods for&#xD;
             contraception during the study until the 8th week post the last administration of&#xD;
             study drug. For men (previous surgical sterilization accepted), will take appropriate&#xD;
             methods for contraception during the study until the 8th week post the last&#xD;
             administration of study drug.&#xD;
&#xD;
         10. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with poor-controlled arterial hypertension (systolic blood pressure &gt; 140&#xD;
             mmHg or diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;&#xD;
             Coronary heart disease, arrhythmia (including QT interval prolongation, for man &gt; 450&#xD;
             ms, for woman &gt; 470 ms), and cardiac dysfunction greater than Class II;&#xD;
&#xD;
          2. Factors affecting the oral medication, such as inability to swallow, chronic diarrhea&#xD;
             and intestinal obstruction;&#xD;
&#xD;
          3. Patients with a clear tendency of gastrointestinal bleeding;&#xD;
&#xD;
          4. Abnormal coagulation function (INR &gt; 1.5×ULN, APTT &gt; 1.5×ULN), with tendency of bleed;&#xD;
&#xD;
          5. Pregnant or lactating women;&#xD;
&#xD;
          6. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaochun Zhang, MD, PhD</last_name>
    <phone>+86 0532 88905767</phone>
    <email>zxc96701@126.com</email>
  </overall_contact>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Municipal Hospital</investigator_affiliation>
    <investigator_full_name>Xiaochun Zhang</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

